Marisa Wexler, MS,  senior science writer—

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Registry data back Soliris, Ultomiris as safe, effective for gMG

Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) are generally safe and effective for easing symptoms of generalized myasthenia gravis (gMG) when used in everyday clinical practice. That’s according to data from the MG SPOTLIGHT Registry (NCT04202341), which was established to assess the long-term effectiveness of both therapies in…

Claseprubart shows good safety, signs of effectiveness in gMG trial

Treatment with the experimental injection therapy claseprubart (DNTH103) was well tolerated and appeared to ease symptoms of generalized myasthenia gravis (gMG) in a Phase 2 clinical trial involving people with the autoimmune neuromuscular condition. That’s according to top-line data announced by the therapy’s developer Dianthus Therapeutics. The…

Gefurulimab found to ease gMG symptoms in global Phase 3 trial

Treatment with gefurulimab, an experimental self-administered injection therapy, outperformed a placebo in easing symptoms of generalized myasthenia gravis (gMG) among people with the chronic autoimmune disease, the results of a Phase 3 clinical trial show. The trial met both its primary and secondary endpoints, or goals, with treatment…

2 new home treatment methods for Rystiggo approved in Japan

Japan’s drug regulatory agency has authorized two new administration methods for Rystiggo (rozanolixizumab) — an approved treatment for generalized myasthenia gravis (gMG) — that people with the chronic autoimmune condition can use at home. These approvals, by the Pharmaceuticals and Medical Devices Agency, or PMDA, will allow gMG…